期刊文献+

金属蛋白酶-9在糖尿病肾病发病机制中的作用 被引量:8

Effect of matrix metalloproteinase-9 on the development of diabetic nephropathy
暂未订购
导出
摘要 目的:探讨大鼠糖尿病肾病发展过程中肾局部金属蛋白酶-9(MMP-9)与糖尿病肾病发生的相关性。方法:健康SD大鼠,随机分成糖尿病组和正常对照组,糖尿病组大鼠采用一次性腹腔内注射链脲佐菌素诱导制造糖尿病大鼠模型。分别于造模后第4、8周通过免疫组织化学方法观察肾局部MMP-9的表达,测其肾小球阳性细胞表达率;应用免疫印迹法对MMP-9在肾组织不同时间点的含量进行定量检测。结果:MMP-9在正常肾小球呈强阳性表达,造模后4、8周末,糖尿病组大鼠MMP-9在肾小球表达均下降。正常对照组MMP-9含量最高,糖尿病4、8周组大鼠肾脏MMP-9含量明显下降。结论:糖尿病肾病时肾组织中MMP-9表达水平降低,可能是糖尿病早期病理改变的重要原因之一。 Objective: To investigate the correlation between matrix metalloproteinase-9 (MMP 9) in the kidneys and the deelopment of nephropathy of diabetic rats. Methods: 20 adult SD rats were randomly divided into 2 groups: normal control :oup and diabetic model group. After diabetic model rats were induced by streptozotocin, immunohistochemistry was used detect MMP 9 expression in the kidneys and positive rate of renal corpusculum was measured at the 4th and the 8th week.Westen blot was employed to analyze the expression of MMP-9 quantitatively. Results : The expression of MMP-9 was significantly weakened in the glomeruli of diabetic rats than that of the control animals (P〈0. 05) by immunohistochemistry.Conclusion: The reduced expression of MMP-9 in kidney tissue of diabetic rats may be one of the main reasons for pathological changes of the renal structure in diabetic nephropathy.
出处 《解剖学杂志》 CAS CSCD 北大核心 2009年第1期35-37,共3页 Chinese Journal of Anatomy
关键词 糖尿病肾病 基质金属蛋白酶-9 大鼠 diabetic nephropathy matrix metalloproteinase-9rat
  • 相关文献

参考文献8

  • 1Ferrario F, Rastaldi M P. Histopathological atlas of renal diseases: diabetic nephropathy[J].Nephrology, 2006,19(1) : 1 -5.
  • 2Boucher E, Mayer G, Londono I, et al. Expression and localization of MT1 -MMP and furin in the glomerular wall of short and long-term diabetic rats[J]. Kidney Int, 2006,69(9):1570-1577.
  • 3McLennan S V, Yue D K, Turtle J R. Effect of glucose on matrix metalloproteinase activity in mesangial cells[J]. Nephron, 1998, 79(3):293-298.
  • 4Wu K, Setty S, Mauer S M, et al. Altered kidney matrix gene expression in early stages of experimental diabetes[J]. Acta Anat, 1997,158(3):155-165.
  • 5Zaoui P, Cantin J F, Alimardani Bessette M, et al. Role of metalloproteases and inhibitors in the occurrence and progression of diabetic renal lesions[J]. Diabetes Metab, 2000,26 (Suppl 4):S25-S29.
  • 6Rysz J, Banach M, Stolarek R A, et al. Serum matrix metalloproteinases MMP-2 and MMP-9 and metallo-proteinase tissue inhibitots TIMP-1 and TIMP-2 in diabetic nephropathy[J].Nephrology, 2007,20(4):444- 452.
  • 7McLennan S V, Kelly D J, Cox A J, et al. Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases [J]. Diabetologia, 2002,45(2) :268-275.
  • 8Van Huyen J P, Viltard M, Nehiri T, et al. Expression of matrix metalloproteinases MMP-2 and MMP-9 is altered during nephrogenesis in fetuses from diabetic rats[J]. Lab Invest, 2007,87 (7) : 680-689.

同被引文献78

引证文献8

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部